These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31815313)

  • 1. Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
    Sharpley FA; De-Silva D; Mahmood S; Sachchithanantham S; Ramsay I; Garcia Mingo A; Worthington S; Hughes D; Mehta A; Kyriakou C; Griffiths PD; Wechalekar AD
    Eur J Haematol; 2020 Mar; 104(3):230-235. PubMed ID: 31815313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus reactivation in lymphoma and myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Massoud R; Assi R; Fares E; Haffar B; Charafeddine M; Kreidieh N; Mahfouz R; Kanj SS; El Zakhem A; Kharfan-Dabaja M; Bazarbachi A; El Cheikh J
    J Clin Virol; 2017 Oct; 95():36-41. PubMed ID: 28843110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barr Syndrome Caused by Cytomegalovirus after Multiple Myeloma Treatment.
    Lu C; Hu H; Ye Y; Cai Z
    Clin Lab; 2024 Jun; 70(6):. PubMed ID: 38868867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?
    Kaya AH; Tekgunduz E; Akpinar S; Batgi H; Bekdemir F; Kayikci O; Namdaroglu S; Ulu BU; Dal MS; Cakar MK; Korkmaz S; Altuntas F
    Transplant Proc; 2017 Oct; 49(8):1911-1915. PubMed ID: 28923647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytomegalovirus reactivation following autologous peripheral blood stem cell transplantation for multiple myeloma in the era of novel chemotherapeutics and tandem transplantation.
    Kim JH; Goulston C; Sanders S; Lampas M; Zangari M; Tricot G; Hanson KE
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1753-8. PubMed ID: 22728249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network.
    Marchesi F; Mengarelli A; Giannotti F; Tendas A; Anaclerico B; Porrini R; Picardi A; Cerchiara E; Dentamaro T; Chierichini A; Romeo A; Cudillo L; Montefusco E; Tirindelli MC; De Fabritiis P; Annino L; Petti MC; Monarca B; Arcese W; Avvisati G;
    Transpl Infect Dis; 2014 Feb; 16(1):158-64. PubMed ID: 24215479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
    Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
    Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab-based regimens.
    De Novellis D; Fontana R; Serio B; Vaccaro E; Guariglia R; Morini D; Rizzo M; Giudice V; Selleri C
    Cancer Med; 2024 Jul; 13(14):e7402. PubMed ID: 39034465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus reactivation accompanied by varicella zoster virus reactivation or reinfection in an adult patient of multiple myeloma during bortezomib therapy.
    Hioki T; Takama H; Makita S; Watanabe K; Watanabe D; Akiyama M
    J Dermatol; 2018 Jan; 45(1):108-109. PubMed ID: 28106266
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
    Marchesi F; Pimpinelli F; Dessanti ML; Gumenyuk S; Palombi F; Pisani F; Romano A; Spadea A; Maschio M; Ensoli F; Mengarelli A
    Transpl Infect Dis; 2014 Dec; 16(6):1032-8. PubMed ID: 25369809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
    Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
    J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution.
    Matsunaga N; Suzuki T; Nishitarumizu N; Nakanishi Y; Kondo A; Kato Y; Ebina T; Marumo Y; Nakamura T; Nakashima T; Kinoshita S; Narita T; Ri M; Kusumoto S; Komatsu H; Iida S
    Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):531-536.e1. PubMed ID: 38653670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
    Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
    Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib-induced cardiogenic shock in a multiple myeloma patient with K light-chain cardiac amyloidosis.
    Dammassa V; Greco A; Totaro R; Colombo CNJ; Raineri C; Camporotondo R; De Ferrari GM; Mojoli F; Arbustini E; Oltrona Visconti L; Tavazzi G
    Ann Hematol; 2022 Sep; 101(9):2087-2088. PubMed ID: 35538262
    [No Abstract]   [Full Text] [Related]  

  • 15. Detection of cytomegalovirus reactivation in cancer patients receiving chemotherapy.
    Kuo CP; Wu CL; Ho HT; Chen CG; Liu SI; Lu YT
    Clin Microbiol Infect; 2008 Mar; 14(3):221-7. PubMed ID: 18070129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
    Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
    J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Light Chain Deposition Disease Mimicking Immunoglobulin Light Chain Amyloidosis: Two Branches of the Same Tree.
    Osanami A; Yano T; Takemura G; Ikeda H; Inyaku M; Toda Y; Kamiyama N; Sugawara H; Gocho Y; Fujito T; Nagano N; Takahashi S; Muranaka A; Tanaka M; Moniwa N; Murase K; Takada K; Kuroda H; Ogawa Y; Miura T
    Circ Cardiovasc Imaging; 2020 Sep; 13(9):e010478. PubMed ID: 32873072
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib therapy-related lung disease in a patient with light chain amyloidosis: A case report.
    Balsman E
    J Oncol Pharm Pract; 2017 Oct; 23(7):545-548. PubMed ID: 27357815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
    Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L
    J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
    Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
    Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.